In 2024, the National Institute on Aging-Alzheimer’s Association (NIA-AA) updated the Amyloid/Tau/Neurodegeneration (ATN) diagnostic framework for AD based on the 2018 criteria (5). Here, MAPT is linked to Alzheimer disease.